Abstract library

380 results for "cancer".
#156 Toxicity, response and survival analyses of Peptide Receptor Radionuclide Therapy (PRRT) in treatment refractory metastatic thyroid cancer using Yttrium-90 and Lutetium-177 Labeled somatostatin analogs
Introduction: Medullary thyroid carcinoma (MTC) represents about 3-16% of thyroid cancer. After first line treatment, therapeutic options for locally recurrent or metastasizing tumors include repeated surgery, whenever possible. Doxorubicin containing chemotherapy regimens in iodine-nonavid differentiated thyroid cancer have poor efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
Authors: Prasad V, Budiawan H, Ali S, Hoersch D, ...
#2024 Metachronous Primary Cancers in Neuroendocrine Tumor Patients
Introduction: Historically there has been an association between neuroendocrine tumours (NETs) and second primary cancers (Stronge et al 2014). However, this has not been well characterised.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Tracey Genus
#1365 Exploring the Rising Incidence of Gastroenteropancreatic Neuroendocrine Tumors According to the Data from Regional Cancer Registry: A Population-Based Analysis of Epidemiology
Introduction: The incidence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) is reported to arise worldwide. Similar tendency is observed in Bulgaria during the recent 6 years.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Paulina Vladova
#2141 Potential Role of SST5TMD4-Derived Peptides in the Malignancy of Neuroendocrine Tumors and Other Endocrine-Related Cancer Cells
Introduction: Extracellular fragments derived from membrane receptors can play relevant functional roles in certain tumoral pathologies and could provide novel diagnostic or therapeutic tools. We have identified a novel truncated somatostatin receptor type 5 variant, sst5TMD4, which is overexpressed and functionally active in different endocrine-related cancers, including neuroendocrine tumors (NETs). Interestingly, sst5TMD4 has 4 transmembrane domains and its C-terminal tail is consequently exposed towards the extracellular matrix, and could, therefore, be the substrate for proteolytic enzymes.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Sergio Pedraza-Arévalo
#2154 Clinical and Morphological Features of Extrapulmonary Small-Cell Cancer
Introduction: Extrapulmonary Small-cell cancer (ESCC) is an extremely rare disease. Usually in the treatment of patients with ESCC approaches to the treatment of patients with small cell lung cancer (SCLC) are used.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Alexey Ivanov
#66 Adrenocortical cancer: a therapeutic approach with everolimus (RAD001)
Introduction: Adrenocortical cancer (ACC) is a rare disease with very poor outcome. ACC responds poorly to standard chemotherapy. Mitotane, used as adjuvant therapy to surgery, prolongs recurrence-free survival, but the response is limited to 23% of patients and resistance occurs in the majority of patients (1). There is no curative therapy for ACC. Pre-clinical studies have shown involvement of both IGF-2/IGF-1R and Akt/mTOR pathways in ACC, and IGF-1R and mTOR inhibitors inhibited cell proliferation of human adrenocortical carcinoma cell lines in vitro (2,3,4).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Maria Gueorguiev
#108 Everolimus (RAD001) induces tumor response in patients with medullary thyroid cancer: an in vivo and in vitro study
Introduction: Medullary thyroid cancer (MTC) is a neuroendocrine tumor (NET) of the thyroid C cells which is known to express somatostatin receptors. Octreotide, a somatostatin analogue exerting both antisecretory and antitumor activity in different types of NETs, has shown low efficacy in MTC. Everolimus (RAD001), an inhibitor of mTOR, has shown antitumor effects in patients with NETs and synergistic effects when combined with octreotide. Until recently, RAD001 has never been evaluated in MTC.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD, PhD Antongiulio Faggiano
#669 Incidence of Second Malignancy in Patients with Neuroendocrine Tumors (NETs) of the Ileum and Colon (MGC)
Introduction: Increased incidence of second malignancy is observed in NETs (Kamp et al 2012).
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Professor Joy Ardill
#864 Diagnostic and Outcome Differences between Sporadic and Familial Cases of Medullary Thyroid Cancer: A Retrospective Cohort Study
Introduction: Hereditary Medullary Thyroid Cancer (MTC) accounts for 20-30% of cases and has some clinically relevant peculiarities.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Guillermo Ropero Luis
#1033 Androgens Regulate SMAD Ubiquitination Regulatory Factor-1 Expression and Prostate Cancer Cell Invasion
Introduction: Prostate cancer is the most commonly diagnosed male cancer and is a hormone-driven disease. Androgens have been recognized as a major promoter of PCa development and progression. However, the mechanism of androgen action in PCa, especially in PCa cell invasion remains largely unclear. SMAD ubiquitination regulatory factor-1 (SMURF1) is a C2-WW-HECT-domain E3 ubiquitin ligase that plays important roles in cancer cell metastasis. Whether there is a relationship between androgens and SMURF1 express is not known.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Gang Xiaokun
Authors: Xiaokun G, Guixia W, ...